Download App
Home › Tools › Site Rotation Tracker

Injection Site Rotation Tracker: Prevent Scar Tissue & Maximize Absorption

Lipohypertrophy — the fatty scar tissue that forms when you inject the same spot repeatedly — can reduce GLP-1 and peptide absorption by 20–40%. This free browser-based tracker enforces a 7-day cooldown across 10 subcutaneous zones so you never need to download a dedicated app.

Total Injections
0
no history yet
Last Injection
—
—
Recommended Next
—
—
Recommended (longest rested)
Available (cooldown clear)
Warming up (3–6 days ago)
On cooldown (<7 days)
Site map — click to log injection
Abdomen
Thigh
Arm & Glute
Injection History

    You have 3 injections logged. Sync your full rotation history, set dose reminders, and view plasma curves in the Halflife app.

    Save history in Halflife app

    Track on the go. The Halflife app adds dose reminders, plasma-level curves, and cloud-synced rotation history across all your compounds.

    Download Free on iOS

    How to Use This Tracker

    1. 1Select your site. Choose a zone from the dropdown or click any tile in the site map. The ★ REC badge marks the most-rested site on every page load — always a reliable default.
    2. 2Confirm the date. Today's date is pre-filled. Backfill a past injection by editing the date field before logging — useful if you missed a session.
    3. 3Log the injection. Click "Log Injection" or tap the site tile directly. The site enters a 7-day cooldown and its status updates immediately across the map.
    4. 4Check back next dose. On your next injection day, the map shows exactly which sites are available, warming up, or still cooling down. Your history is saved in this browser — no account needed.
    Important: All data is stored in your browser's localStorage. Clearing browser data or switching devices will erase your history. For persistent cross-device tracking, use the Halflife iOS app.

    What Is Lipohypertrophy?

    Lipohypertrophy is the localized accumulation of hypertrophied subcutaneous adipose tissue caused by two converging mechanisms: repeated mechanical trauma from needle penetration disrupting local connective tissue architecture, and the direct lipogenic (fat-stimulating) effect of injected substances on surrounding adipocytes. It is most extensively documented in insulin users but is equally relevant to anyone self-administering GLP-1 receptor agonists, growth hormone peptides, or any subcutaneous compound on a recurring schedule.

    Clinically, lipohypertrophy presents as a nodular, rubbery, or slightly raised mass beneath the skin that persists for weeks to months. It often feels firmer than surrounding subcutaneous fat on palpation. Affected areas develop increased local fat deposition alongside collagen deposition and reduced capillary density — the last point being critical, because reduced vascularity directly impairs drug absorption.

    Incidence is higher than most users expect. Studies in insulin-dependent populations report lipohypertrophy rates of 22–70% depending on injection behavior. The primary driver is not the drug itself, but the rotation pattern — or lack of one.

    The Pain-Free Paradox

    One of the most clinically significant features of lipohypertrophy is that affected tissue is less sensitive to needle insertion than surrounding healthy fat. The nerve endings in fibrotic, hypertrophic tissue are disrupted, reducing the discomfort of injecting there. This creates a self-reinforcing cycle: you inject into the site that hurts less, which causes more lipohypertrophy, which makes it hurt even less, drawing you back to the same spot repeatedly. Breaking this cycle requires deliberate, tracked rotation — which is precisely what this tool enforces.

    Risk FactorRelative RiskMitigation
    Same anatomical zone > 2× per weekHighRotate through at least 3–4 zones
    Less than 1 cm spacing within a zoneHighUse grid method; advance ≥ 2 cm per injection
    Returning to same site in under 7 daysModerate–HighUse this tracker to enforce cooldown
    Needle reuse across sessionsModerateSingle-use needles only — barbed tips increase risk 3×
    Injecting cold drug (straight from fridge)LowAllow vial or pen to reach room temperature first
    No intra-zone rotation (only left/right)ModerateApply clockwork or grid method within each quadrant

    Best Subcutaneous Injection Sites: Abdomen, Thigh, Upper Arm

    Not all subcutaneous sites absorb drugs equally. The periumbilical abdomen is the gold-standard for most peptides and GLP-1 agonists due to its dense subdermal vasculature. Thigh and arm sites are valuable rotation partners, with slightly reduced but still clinically effective absorption profiles. Gluteal sites are rarely used for aqueous compounds — they are better suited to oil-based depot formulations.

    SiteRelative AbsorptionTime to PeakBest ForNotes
    Abdomen (periumbilical)Fastest — 100% baseline30–60 minGLP-1s, insulin analogs, most peptidesAvoid 5 cm radius directly around navel; 4 quadrants available
    Lateral Thigh~85% of abdominal rate45–90 minLong-acting compounds, BPC-157, alternating weekly dosesLarge surface area allows many sub-zones; avoid inner thigh
    Lateral Upper Arm~82% of abdominal rate45–75 minPre-filled pens (Ozempic, Wegovy), once-weekly dosesDifficult self-injection angle; pre-loaded auto-injectors preferred
    Ventrogluteal~78% of abdominal rate60–120 minOil-based depot formulationsRarely used for aqueous peptides; better for testosterone esters

    A 2023 review in Diabetes, Obesity and Metabolism found no statistically significant pharmacokinetic difference between abdominal and thigh sites for once-weekly GLP-1 agonist formulations in healthy subcutaneous tissue. The clinical consensus still recommends multi-site rotation not for absorption optimization in healthy tissue, but for tissue preservation over the months and years of continuous therapy.

    The Clockwork Method: Systematic Rotation Around the Navel

    The clockwork method is the most practical and scalable approach to intra-zone rotation. Treat each abdominal quadrant as a clock face, with the center of the quadrant as the origin point. Assign each injection to a "clock position" — 12, 1, 2, 3 o'clock, and so on — working clockwise with each successive dose. On a once-weekly protocol confined to a single quadrant, this provides 12 weeks of rotation before any exact position repeats.

    • 1 quadrant × 12 positions = 12 weeks before repeat (single-quadrant weekly protocol)
    • 4 quadrants × 12 positions = 48 weeks before any abdominal position repeats
    • Add 6 thigh positions + 4 arm positions: 58 discrete sites total — over a year's worth of rotation on a weekly schedule
    • Minimum safe position radius: the needle entry point should be at least 2 cm from the previous clock position in the same quadrant

    The Grid Method: Precision Spacing for Daily Protocols

    For daily-injection compounds (BPC-157, TB-500, Ipamorelin/CJC stacks), the clockwork method may not provide enough granularity. The grid method divides each abdominal quadrant into a 3×3 cm grid of nine distinct squares. Each square receives one injection per cycle, yielding nine positions per quadrant and 36 abdominal positions total. On a daily protocol with full 10-site rotation between abdomen, thighs, and arms, you can theoretically go weeks before returning to any given grid square.

    Practical tip: You don't need to physically draw a grid. Use anatomical landmarks — the navel, the inguinal crease, the lateral hip crest — to mentally divide each quadrant into a top-left, top-center, top-right, middle-left, etc. A brief pause before injecting to consciously choose a position different from last time is all the technique requires.

    The 7-Day Cooldown Rule: Why the Minimum Exists

    The 7-day minimum interval before returning to a previously injected site is grounded in the three-phase wound-healing cycle of subcutaneous tissue. This cycle applies to every needle puncture, regardless of how small the gauge or how careful the injection technique.

    • Phase 1: 0–72 hours — Inflammatory Mast cell degranulation, histamine and prostaglandin release, local edema, and increased capillary permeability. Drug absorption in this window is altered and unpredictable. Re-injecting here adds insult to actively inflamed tissue.
    • Phase 2: Days 3–7 — Proliferative Fibroblast activity peaks; early collagen deposition begins. The tissue is remodeling. Re-injecting during this phase disrupts collagen organization and is the primary trigger for fibrotic scar formation over time.
    • Phase 3: Days 7–21 — Remodeling Collagen matures, capillary density normalizes, and local architecture returns to baseline. Sites that receive a second injection before this phase completes are demonstrably more prone to lipohypertrophy with repeated cycles.

    The 7-day cooldown marks the boundary between Phase 2 and Phase 3 — the earliest point at which the tissue has completed its initial structural repair and can safely receive another injection without compounding fibrotic risk.

    10-Site Weekly Rotation Schedule for GLP-1 Agonists

    The following table shows a simple 10-week rotation cycle for semaglutide, tirzepatide, or retatrutide — one injection per week, one site per week, returning to Week 1 after Week 10. Each site gets a full 70-day rest before being used again.

    WeekInjection SiteDays Since Last Use at Injection
    Week 1Abdomen — Upper Right70 days (on cycle 2+)
    Week 2Abdomen — Upper Left70 days
    Week 3Abdomen — Lower Right70 days
    Week 4Abdomen — Lower Left70 days
    Week 5Thigh — Right (lateral)70 days
    Week 6Thigh — Left (lateral)70 days
    Week 7Arm — Right (lateral)70 days
    Week 8Arm — Left (lateral)70 days
    Week 9Glute — Right70 days
    Week 10Glute — Left70 days

    Injection Technique for Maximum Absorption

    Rotation strategy is necessary but not sufficient. How you inject matters as much as where you inject. Poor technique in a perfectly rotated site still delivers suboptimal results. The following checklist reflects current ADA subcutaneous injection technique recommendations and standard peptide administration protocols.

    StepRecommended TechniqueWhy It Matters
    Alcohol prepSwab site; let dry 30 secondsWet alcohol can sting and transiently alter epidermal permeability; drying takes < 30 sec
    Pinch2–3 cm skin fold between thumb and index fingerLifts the subcutaneous layer away from muscle; critical for lean individuals or short needles
    Needle angle90° for ≥ 8 mm needles; 45° for shorterDepth control by body habitus and needle length; 90° is standard for most insulin pen needles (4–6 mm)
    Insertion speedQuick and decisiveSlow insertion increases needle drag, tissue tearing, and local trauma per unit depth
    Post-injection hold5–10 sec before withdrawalAllows pressure to equalize; prevents drug backflow into the needle track
    Post-injection pressureLight pressure — no rubbingRubbing accelerates local absorption erratically and can disperse drug into unintended tissue planes
    Needle disposalSingle-use only — sharps binReused needles develop microscopic barbs that dramatically increase tissue trauma and lipohypertrophy risk
    Drug temperatureRoom temperature before injectingCold drug is more viscous, requires more force to inject, and may cause localized discomfort and vasospasm

    Frequently Asked Questions

    What is lipohypertrophy and how do I know if I have it?
    Lipohypertrophy is the localized buildup of hypertrophied subcutaneous fat caused by repeated needle trauma and the lipogenic effects of injected substances. You can identify it by palpating your injection area: affected tissue feels nodular, rubbery, or slightly raised versus surrounding fat. It is often less painful on injection — the pain-free paradox that drives overuse. Other signs include a visible bump that persists for weeks and a subjective sense that the drug is working less well than before. Blanco et al. (2013) found lipohypertrophy in over 50% of insulin users who did not systematically rotate sites.
    How many injection sites should I rotate between for a weekly GLP-1?
    The clinical minimum for a once-weekly protocol is 3–4 anatomical zones. This tracker provides 10 zones — four abdominal quadrants, two lateral thighs, two lateral arms, and two gluteal sites. Rotating through all 10 means a 70-day rest period per site, which is well above any clinically meaningful threshold. If you only use 3 zones, you return to each every 3 weeks, which is sufficient but leaves no buffer if a site develops early fibrotic changes. For daily protocols, the more sites the better — the grid method within each zone can provide dozens of distinct positions.
    Does injection site affect how well semaglutide or tirzepatide works?
    In healthy subcutaneous tissue, the pharmacokinetic difference between abdominal and thigh sites for once-weekly GLP-1s is small — within approximately 15%. A 2023 review in Diabetes, Obesity and Metabolism found no statistically significant difference for weekly formulations. However, injecting into lipohypertrophic tissue can reduce absorption by 20–40%, creating the impression that the drug has stopped working. Before requesting a dose increase from your prescriber, audit your injection habits and switch to a healthy site for 2–4 weeks. If efficacy recovers, lipohypertrophy was the cause.
    How long does lipohypertrophy take to heal?
    Mild lipohypertrophy begins to resolve within 4–8 weeks of complete site avoidance. Established, well-defined lumps may take up to 12 weeks to normalize. During this period, the affected site should be removed from rotation entirely — not just placed on the standard 7-day cooldown. The 7-day minimum applies to healthy tissue. Lipohypertrophic sites require sustained rest until they feel indistinguishable from the surrounding subcutaneous layer on palpation. Gentle massage of the surrounding (not the lump itself) may help with early cases.
    What is the minimum spacing between injections in the same zone?
    The ADA injection technique guidelines recommend a minimum of 1 cm between any two injection marks within the same anatomical zone. Practically, 2–3 cm is preferred. The clockwork method (advancing one clock-face position per injection within a quadrant) naturally achieves this — adjacent clock positions on a 5 cm radius quadrant are approximately 2.5 cm apart. The grid method (3×3 cm squares) provides an even more explicit spatial framework, particularly for daily-injection protocols where intra-zone density is higher.
    Can I always inject in my abdomen if I rotate all four quadrants?
    Yes. Rotating through all four abdominal quadrants gives a minimum 4-week return interval per quadrant, exceeding the 7-day floor. With the clockwork method adding 12 distinct positions per quadrant, each exact position sees a 48-week return interval within the abdomen alone. The abdomen is the preferred site for most users due to its fastest and most consistent absorption, and limiting yourself to abdominal sites is entirely clinically appropriate — as long as you apply systematic intra-zone rotation and maintain the spacing rules above.
    Why doesn't my GLP-1 seem to be working as well as it used to?
    Reduced GLP-1 efficacy over time has multiple causes — metabolic adaptation, weight-set-point changes, dose timing — but lipohypertrophy from poor site rotation is one of the most overlooked and correctable causes. Fibrotic subcutaneous tissue has reduced capillary density, meaning the drug enters the bloodstream more slowly and at a lower peak concentration, blunting both appetite suppression and glycemic effects. This is a well-documented phenomenon in insulin management literature and is directly applicable to GLP-1 users on long-term therapy. Switch to a confirmed healthy site for 2–4 consecutive weeks before concluding that the drug has lost efficacy.
    Is the abdomen or thigh better for GLP-1 injections?
    For most users, the abdomen provides the fastest and most consistent absorption due to the dense periumbilical microvascular network. The lateral thigh offers slightly slower absorption (~85% of abdominal rate), which some users find reduces acute GI side effects — the blunted peak concentration is occasionally beneficial in the early weeks of dose escalation. The ideal clinical approach is to use both systematically: rotate between abdominal quadrants and lateral thigh sites to simultaneously maximize tissue protection and maintain pharmacokinetic predictability across doses.
    What is the clockwork rotation method?
    The clockwork method treats each abdominal quadrant as a clock face. Starting at 12 o'clock (the outermost point of the quadrant nearest the midline) and advancing clockwise by one position per injection, you use 12 distinct positions before the cycle repeats. On a weekly protocol, a single abdominal quadrant provides 12 weeks of rotation before any exact position is revisited. Combined with all four abdominal quadrants, the rotation extends to 48 weeks — nearly a full year of abdominal injections before any spot repeats. Add thigh and arm sites and the effective cycle exceeds a year.
    Do I need a separate tracker if I am using two different peptides?
    No. Injection sites belong to tissue, not to compounds. If you inject BPC-157 into your right thigh in the morning and tirzepatide into the same zone in the evening, that tissue has been mechanically stressed twice in one day regardless of which substance was used. This tracker logs by anatomical site — the physiologically correct approach. Log every subcutaneous injection you give, regardless of the compound, and the 7-day cooldown will accurately reflect total cumulative tissue burden at each site. If you need to track different compounds separately, use the note field in the Halflife app.
    Related Tools
    Reconstitution Calculator GLP-1 Escalation Calculator Half-Life Calculator Peptide Stack Planner Tirzepatide Semaglutide

    The 7-day cooldown is a general evidence-based guideline. Always follow your prescriber's specific instructions. Lipohypertrophy incidence data from Blanco et al. (2013) and Hauner et al. (1987). Absorption rate comparisons based on Frid et al. (2010) and ADA Standards of Medical Care. Not medical advice.

    © 2026 Halflife Labs — halflife-labs.comVienna, Austria